Stifel analyst Daniel Arias lowered the firm’s price target on Illumina to $235 from $285 and keeps a Buy rating on the shares. The company’s Q4 results were "slightly above" pre-announced levels and the FY23 guidance is unchanged, though the Q1 outlook is "pretty soft," the analyst tells investors. The Nova X order ramp will be "production constrained, not demand constrained," but on the consumables side "we are less bullish," Stifel added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ILMN:
- Illumina price target raised to $303 from $284 at RBC Capital
- Illumina price target raised to $230 from $210 at BofA
- Illumina price target lowered to $150 from $160 at Barclays
- Illumina sees FY23 adjusted EPS $1.25-$1.50, consensus $1.98
- Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022